Alzinova AB (publ)
Author: Alpha
Alzinova potentially has a promising vaccine for Alzheimer in its portfolio. The company plans to sign a partner agreement before Phase 2 trial which could boost the share price.
However key stakeholders have a questionable reputation from involvement in; Vivesto (Oasmia), Anima Group, Peptonic Medical and Rosland Capital. Alzinova's last right issue resulted in 50% dilution as the number of shares doubled. The underwriters, including existing shareholders, received a 20% fee for the underwritten amount, almost 10% of the company at a market cap of 100Mkr.
Negative given the background of the people behind the company.
0